FDA Approves Xyrem (sodium oxybate) Oral Solution Generic with a REMS Program
January 18, 2017 -- The FDA has approved the first generic version of Xyrem (sodium oxybate) Oral Solution, to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy, which is a potentially debilitating disease. Cataplexy is a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2017 Category: Pharmaceuticals Source Type: news
FDA approves generic version of Jazz Pharma's sleep disorder drug
(Reuters) - The U.S. Food and Drug Administration said it had approved the first generic version of Xyrem, Jazz Pharmaceuticals Plc's drug to treat patients with narcolepsy, a kind of sleeping disorder. (Source: Reuters: Health)
Source: Reuters: Health - January 17, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Patients recovering from depression show improvements in memory from the drug modafinil
(University of Cambridge) Modafinil, a drug used to treat narcolepsy -- excessive daytime sleepiness -- can improve memory in patients recovering from depression, according to new research from the University of Cambridge. The findings, published today in the journal Biological Psychiatry: CNNI, result from a randomized, double-blind, placebo-controlled study and offer hope of a treatment for some of the cognitive symptoms of depression. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 16, 2017 Category: Global & Universal Source Type: news
Scientists Identified 8 Genes That May Be Causing A Lot Of Sleep Problems
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com.
Sarah DiGiulio is The Huffington Post’s sleep reporter. You can contact her at sarah.digiulio@huffingtonpost.com.
function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+...
Source: Healthy Living - The Huffington Post - January 12, 2017 Category: Consumer Health News Source Type: news
Scientists Identified 8 Genes That May Be Causing A Lot Of Sleep Problems
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com.
Sarah DiGiulio is The Huffington Post’s sleep reporter. You can contact her at sarah.digiulio@huffingtonpost.com.
function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+...
Source: Science - The Huffington Post - January 12, 2017 Category: Science Source Type: news
Medical News Today: Could a narcolepsy drug help combat food addiction?
Researchers found that a prescription drug used to treat narcolepsy reduced impulsivity in men, which is considered a driver of food addiction and obesity. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 28, 2016 Category: Consumer Health News Tags: Obesity / Weight Loss / Fitness Source Type: news
NHS England to press ahead with court appeal
NHS England will press ahead with a Court of Appeal case against a judge ’s ruling that it should commission a drug for a teenager with narcolepsy that it has since decided to routinely provide. (Source: HSJ)
Source: HSJ - December 21, 2016 Category: UK Health Source Type: news
Flamel Technologies dose first patient in Phase III narcolepsy trial
Flamel Technologies (NSDQ:FLML) said today that the 1st patient in its Rest-On phase III clinical trial was dosed with FT218, sodium oxybate, for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients.The Lyon, France-based company developed the controlled-release oral formulation of sodium oxybate using its Micropump technology.
The randomized, double-blind trial has enrolled 264 patients to assess the safety and efficacy of a once nightly dosage of the oral suspension of sodium oxybate. The study will be conducted at 50-60 sites throughout the U.S., Europe and Canada, according to Flamel.
Get ...
Source: Mass Device - December 16, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Flamel Technologies Source Type: news
Warwick University experts say sleep disorder drug also reduces hunger cravings
Researchers from Warwick University and Imperial College London found giving overweight adults Modafinil, generally used to treat narcolepsy, helps to reduce impulsive behaviour. (Source: the Mail online | Health)
Source: the Mail online | Health - December 14, 2016 Category: Consumer Health News Source Type: news
Drug for narcolepsy could help food addicts lose weight
Overweight people could be given help with the discovery that a drug used for sleep disorder could also reduce the impulse for food, report scientists. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 13, 2016 Category: Science Source Type: news
Drug for narcolepsy could help food addicts lose weight
(University of Warwick) Overweight people could be given help with the discovery that a drug used for sleep disorder could also reduce the impulse for food. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 13, 2016 Category: Global & Universal Source Type: news
Kendall Jenner’s Sleep Paralysis Is Actually Pretty Common
On Sunday, Kendall Jenner opened up about struggling with a sleep problem that is thought to affect nearly eight percent of the general population: sleep paralysis.
“I wake up in the middle of the night and I can’t move,” Jenner said in the latest episode of Keeping Up With the Kardashians. “I’m freaking out.”
Indeed, sleep paralysis is a phenomenon where you are awake and conscious, but your body is paralyzed (except for your eyes) and between 80 and 90 percent of the time you experience nightmares or disturbing hallucinations.
“They [can be] scary experiences,” B...
Source: Science - The Huffington Post - November 8, 2016 Category: Science Source Type: news
Kendall Jenner’s Sleep Paralysis Is Actually Pretty Common
On Sunday, Kendall Jenner opened up about struggling with a sleep problem that is thought to affect nearly eight percent of the general population: sleep paralysis.
“I wake up in the middle of the night and I can’t move,” Jenner said in the latest episode of Keeping Up With the Kardashians. “I’m freaking out.”
Indeed, sleep paralysis is a phenomenon where you are awake and conscious, but your body is paralyzed (except for your eyes) and between 80 and 90 percent of the time you experience nightmares or disturbing hallucinations.
“They [can be] scary experiences,” B...
Source: Healthy Living - The Huffington Post - November 8, 2016 Category: Consumer Health News Source Type: news
Theranexus begins enrolment for Phase II trial of THN102 to treat narcolepsy-caused sleepiness
Theranexus has enrolled the first patient for its Phase II clinical study of THN102 to treat excessive daytime sleepiness associated with narcolepsy in adult patients. (Source: Drug Development Technology)
Source: Drug Development Technology - October 31, 2016 Category: Pharmaceuticals Source Type: news
[Editors' Choice] Autoimmunity in narcolepsy
Author: Lisa D. Chong (Source: ScienceNOW)
Source: ScienceNOW - October 6, 2016 Category: Science Authors: Lisa D. Chong Tags: Neuroimmunology Source Type: news
